This morning, HARV released estimated and unaudited revenue numbers for its second quarter, saying it expects the topline will fall between $75-million and $77-million, which would represent an improvement of at least 47 per cent over the same period last year.
Malik says this figure range is significantly above the $59-million he had modeled
“Harvest continues to aggressively expand its operational footprint, leading to strong growth in financial performance,” the analyst writes. “The Company remains on track to execute on its growth strategy and build one of the largest vertically integrated networks in the US.”
In a research update to clients today, Malik maintained his “Buy” rating and one-year price target of $19.00 on Harvest Health, implying a return of 146.1 per cent at the time of publication.
Malik thinks HARV will post EBITDA of $70-million on revenue of $354-million in fiscal 2019. He expects those numbers will improve to EBITDA of $286-million on a topline of $914-million the following year.
The analyst says acquisitions and organic expansion have led to the growth at HARV.
“In addition to acquisitions, Harvest continues to expand its retail footprint by operationalizing existing licenses, Malik adds. “In addition, we believe Harvest’s wholesale business is performing well.”
About Harvest Health & Recreation, Inc.
Headquartered in Tempe, Arizona, Harvest Health & Recreation, Inc. is a multi-state cannabis operator (MSO) and vertically-integrated cannabis company. Subject to completion of announced acquisitions, Harvest will have one of the largest footprints in the U.S., with rights to more than 210 facilities, of which approximately 135 are retail locations, and more than 1,695 employees across 18 states and territories. Since 2011, the company has been committed to expanding its Harvest House of Cannabis retail and wholesale presence throughout the U.S., acquiring, creating and growing leading brands for patients and consumers nationally and continuing on a path of profitable growth. Harvest’s mission is to improve lives through the goodness of cannabis and is focused on its vision to become the most valuable cannabis company in the world.
Following the company's fourth quarter results, Scotia analyst Konark Gupta has raised his price target on MDA (MDA Stock Quote,… [Read More]
Following the company's fourth quarter results, National Bank Financial analyst Richard Tse has raised his price target on Constellation Software… [Read More]
Following the company's fourth quarter results, Ventum Capital Markets analyst Andrew Semple has downgraded and cut his price target on… [Read More]
Following the company's third quarter results, Ventum Capital Markets analyst Amr Ezzat has maintained his "Buy" rating and "Top Pick"… [Read More]
A dice roll. That's what stock pundit Jim Cramer calls BlackBerry (BlackBerry Stock Quote, Chart, News, Analysts, Financials NYSE:BB) stock… [Read More]
Beacon Securities analyst Russell Stanley believes there is money to be made on Intermap Technologies (Intermap Technologies Stock Quote, Chart,… [Read More]